The registered shares of Actelion Ltd were listed on the SWX New Market on April 6, 2000 (symbol: ATLN). A total of 1,000,000 primary shares were placed at the company’s Initial Public Offering (IPO), at a price of CHF 260 per share, raising CHF 246.6 million.

On 8 July 2008, the Management Committee of the SIX Swiss Exchange added Actelion shares (ATLN, CH0010532478) to the Swiss Market Index SMI®. Actelion shares have traded as part of the SMI since 22nd September 2008.

On 22 August 2016, Actelion announced that it completed its first-line share purchase program (initiated on 9 December 2013) on 19 August 2016. During this time, Actelion purchased 10,000,000 of its own shares, which represents 8.31% of the issued shares at the time of the start of the share purchases. The shares were used for the reactive servicing of existing employee option and share ownership programs.

On 8 April 2015, Actelion commenced the repurchase of up to 10 million shares of the company’s common stock over the next three years via a second trading line on the SIX Swiss exchange. At subsequent Annual General Meetings, the Board of Directors will propose that the shares bought through this process be cancelled and the issued share capital reduced accordingly.

Actelion Ltd is part of the following indices: SMI, SPI, SLI, SPIMLC, SPI20, SPISMC, SXXP, SXDP, SBC100, SNSPIX, SMHCAX, SLDI, SXI LIFE SCIENCES and SXI Bio+Medtech. Actelion is traded under the following symbols: Reuters ATLN.S/ Bloomberg ATLN.

KEY SHARE DATA

As of 30 September 2016  
Shares outstanding 107.8 million
Closing share price CHF 168.20
Market capitalization CHF 18.1 billion
52-week high CHF 173.80
52-week low CHF 122.50
YTD price change 23%
Average daily volume

376,000

Free float 96.17%

Shareholdings

As of 30 September 2016  
Number of registered shareholders 11,481

Major Shareholders

As of 30 September 2016  
Management and Directors > 5 %
Actelion > 3 %
Rudolf Maag > 3 %
Blackrock > 5 % 

 This content is updated on a quarterly basis.

 

SIX NOTIFICATION

In compliance with the SIX disclosure notification please find further information on the exercise of financial instruments related to the Company's Employee Share Option and Share Plans.

Drug Safety Coordinator, Global Drug Safety 

 

"At Actelion we are given the chance to be proactive and improve ourselves."